Therefore, SGLT2 inhibitors can effectively reduce the hospitalization rate or mortality rate of heart failure patients but have no significant improvement on atherosclerosis because their hypoglycemic effect is not obvious [55–57]. This evidence concerns the gene SLC5A2 and heart failure.